Penumbra, Inc.
PEN
Rang in Aktien
#1697
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Aktienkurs
$320.95
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$12.64B
Veränderung (1 Tag)
-0.15%
Veränderung (1 Jahr)
28.90%
Land
US
Handel Penumbra, Inc. (PEN)
Kategorie
Healthcare
Operative Marge für Penumbra, Inc. (PEN)
Operative Marge zum October 2026 TTM: 12.45%
Laut den neuesten Finanzberichten und dem Aktienkurs von Penumbra, Inc. beträgt die aktuelle operative Marge (TTM) 12.45%. Am Ende des Jahres 2023 lag die operative Marge bei 6.95%.
Historie der operativen Marge von Penumbra, Inc. von 2012 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 12.45% | 1,496.15% |
| 2024 | 0.78% | -88.78% |
| 2023 | 6.95% | 865.28% |
| 2022 | 0.72% | -172.00% |
| 2021 | -1.00% | -85.61% |
| 2020 | -6.95% | -180.07% |
| 2019 | 8.68% | -4,668.42% |
| 2018 | -0.19% | -154.29% |
| 2017 | 0.35% | -168.63% |
| 2016 | -0.51% | -122.67% |
| 2015 | 2.25% | -6.25% |
| 2014 | 2.40% | -288.98% |
| 2013 | -1.27% | -127.08% |
| 2012 | 4.69% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 17.03% | -98.63% |
US
|
|
| 17.86% | -98.57% |
IE
|
|
| 22.03% | -98.23% |
US
|
|
| 21.46% | -98.28% |
US
|
|
| 0.00% | - |
DE
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.